TAR-210

TAR-210 (JNJ-42756493) is a small molecule (intravesical drug-releasing system) developed by Janssen Research & Development. Its target is FGFR2 (the sponsor names FGFR (fibroblast growth factor receptor)). The sponsor states: An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations. ClinicalTrials.gov describes the intervention as: TAR-210 will be administered intravesically. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT06919965, plans to enrol 220 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.